Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials
Our findings support that changes in plasma p-tau217 represent a robust endpoint for clinical trials targeting CU or CI individuals with Aβ pathology.
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 0
- Publications
- 1
- Citations
- 0
- Institution
- Instituto do Cérebro
External Links
Identifiers
- ORCID
- 0000-0002-7378-3830
Impact Metrics
h-index
0
h-index: Number of publications with at least h citations each.